DEF: Merit Medical Reports Record 2025 Revenue, CEO Transition

Sentiment:

Proxy Statement 31 March 2026 4:22 PM

📋All filings for Merit Medical Systems INC

Merit Medical Systems, Inc. announced record-setting 2025 revenue of $1.516 billion, strong profitability, and a successful CEO transition to Martha G. Aronson, alongside proposals for its 2026 Annual Meeting.

Better than expectedAchieved record-setting revenue of $1.516 billion in 2025, an 11.8% increase over 2024, driven by stronger-than-anticipated demand in the U.S. and favorable international sales trends, particularly in the EMEA region.Delivered better-than-expected financial results in the fourth quarter of 2025.Non-GAAP operating margin improved by 130 basis points year-over-year.Strong free cash flow generation of over $215 million, up 16% year-over-year.Non-GAAP EPS of $3.83, up 11% year-over-year.Successfully completed the second year of the Continued Growth Initiatives Program, remaining on track for all three-year targets.

Summary

Achieved record-setting revenue of $1.516 billion in 2025, an 11.8% increase compared to $1.357 billion in 2024, driven by stronger-than-anticipated demand in the U.S. and favorable international sales trends.
Successfully completed the second year of the Continued Growth Initiatives Program (CGI Program), strengthening profitability, delivering top-line growth, and driving continuous innovation, remaining on track for all three-year targets ending December 31, 2026.
Completed a leadership transition with Martha G. Aronson appointed President and Chief Executive Officer in October 2025, succeeding Fred P. Lampropoulos, who transitioned to Executive Chair and later resigned from the Board.
Executed two strategic acquisitions in 2025: Biolife Delaware, L.L.C. (hemostatic devices) for $120 million upfront cash plus $7.2 million adjustments, and the C2 CryoBalloon device and related technology from Pentax of America, Inc. for $19 million cash at closing with potential contingent payments up to $3 million.
Reported non-GAAP operating margin improvement of 130 basis points year-over-year and strong free cash flow generation of over $215 million, up 16% year-over-year.
Proposed the approval of the 2026 Equity Incentive Plan, authorizing 2,700,000 shares, and the 2026 Employee Stock Purchase Plan, authorizing 500,000 shares, to enhance employee and shareholder alignment and talent retention.
The 2026 Annual Meeting of Shareholders will be held virtually on May 13, 2026, to elect four directors, approve executive compensation on an advisory basis, and ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong filing, highlighting robust financial performance, successful leadership transition, and strategic growth initiatives. The company's commitment to corporate governance and sustainability further enhances its long-term appeal, despite the relative underperformance in TSR compared to the broader peer group.

Positives

Record-setting revenue of $1.516 billion in 2025, an 11.8% increase over 2024.
Achieved operating margin and free cash flow levels that yielded shareholder returns at the upper end of the peer group.
Successfully completed the second year of the CGI Program, demonstrating significant progress towards financial targets.
Successful leadership transition with Martha G. Aronson appointed as President and CEO, bringing extensive global healthcare and executive leadership experience.
Strategic acquisitions of Biolife Delaware, L.L.C. ($120 million upfront cash plus $7.2 million adjustments) and Pentax's C2 CryoBalloon device ($19 million cash at closing plus potential $3 million contingent payments) expanded the product portfolio.
Launched new products including Ventrax Delivery System, MAK Gold Mini Access Kits, Prelude Wave Hydrophilic Sheath Introducer with SnapFix technology, and the 10FoRe hemostasis valve.
Achieved CE Mark for Embosphere Microspheres for genicular artery embolization to treat knee osteoarthritis.
Commenced construction of a 212,000 square foot distribution facility to accommodate future growth.
Strong shareholder support for the executive compensation program, with approximately 97% of shareholders voting in favor in 2025.
Enhanced corporate governance practices, including separation of CEO and Chair roles, a highly independent Board, and robust stock ownership guidelines.

Risks

Cybersecurity risks: The company faces potential cyber risks and digital vulnerabilities, requiring ongoing assessment and mitigation efforts.
Legal and regulatory compliance: Risks associated with compliance with various laws and regulations, including the U.S. Anti-Kickback Statute, False Claims Act, Foreign Corrupt Practices Act, export/import regulations, advertising/promotion laws, and Sunshine/Transparency Laws.
Supply chain labor practices: Potential risks of unlawful or harmful labor practices within the supply chain, which the company assesses through its Human Rights and Labor Standards Policy.
Climate change: Climate risks and opportunities impact long-term resiliency, requiring proactive actions to mitigate and adapt.
Acquisition integration: Challenges associated with integrating acquired businesses and achieving anticipated synergies.

Future Outlook

The company anticipates continued sustainable growth in profitability, driven by ongoing execution of its CGI Program, strategic acquisitions, and a focus on higher-margin therapeutic products. It expects to achieve its three-year targets for revenue, operating margin, and free cash flow generation by the end of 2026.

Management Comments

"We finished 2025 with strong momentum by delivering better-than-expected financial results in the fourth quarter, reflecting continued strong execution." F. Ann Millner, Ed.D., Chair of the Board
"Ms. Aronson brings the right combination of experience, skills and attributes to guide Merit through the next phase of its growth journey." F. Ann Millner, Ed.D., Chair of the Board
"Our operating and financial results for full-year 2025 kept us on track towards achieving each of the programs three-year targets relating to revenue, operating margin and free cash flow generation."

Industry Context

StockSavvy.ai notes that Merit Medical's strategic focus on high-margin therapeutic products and continued innovation aligns with broader trends in the medical device industry, where companies are increasingly seeking specialized, value-added solutions to drive growth and profitability. The successful integration of acquisitions like Biolife and Pentax's C2 CryoBalloon device positions Merit to expand its market share in key interventional and gastrointestinal segments, a common growth strategy among industry leaders. The company's emphasis on sustainability and corporate governance also reflects a growing industry-wide commitment to ESG factors.

Comparison to Industry Standards

Merit Medical's 5-year Total Shareholder Return (TSR) of 59% (December 31, 2020, to December 31, 2025) significantly underperformed the NASDAQ Peer Group (SIC 3840-3849 US Companies Surgical, Medical, and Dental Instruments and Supplies) TSR of 158.70% for the same period.
The company's non-GAAP operating margin of 20.3% in 2025, an improvement of 130 basis points year-over-year, indicates strong operational efficiency, aligning with industry efforts to enhance profitability through cost management and strategic initiatives.
Merit Medical benchmarks its executive compensation against a peer group including companies like CONMED Corporation, Globus Medical, Inc., Haemonetics Corporation, ICU Medical, Inc., and Penumbra, Inc., suggesting a competitive approach to attracting and retaining talent within the medical device sector.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President and Chief Executive Officer	Fred P. Lampropoulos	Martha G. Aronson	October 3, 2025	Leadership transition plan; Mr. Lampropoulos retired from these roles.
Executive Chair of the Board	NA	Fred P. Lampropoulos	October 3, 2025	Transition from President and CEO role.
Director and Chair of the Board	Fred P. Lampropoulos	NA	January 4, 2026	Resignation from the Board.
Chair of the Board	NA	F. Ann Millner, Ed.D.	January 5, 2026	Appointment following Mr. Lampropoulos's resignation; previously Lead Independent Director.
Director	David K. Floyd	NA	May 13, 2026 (Annual Meeting)	Term of office does not continue.
Chief Commercial Officer	NA	C. Adam Smith	May 2025	Promotion from Executive Vice President, U.S. and EMEA.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	Separation of CEO and Chair of the Board positions in 2025, with an independent Chair (F. Ann Millner, Ed.D.) appointed on January 5, 2026.	2025 (separation), January 5, 2026 (Chair appointment)	Enhances independent oversight and strengthens corporate governance by clearly delineating leadership roles.
Board Composition	Six new directors appointed since 2020, increasing diversity of backgrounds and perspectives, and adding critical medical industry and operational oversight expertise. The average Board tenure of independent directors is approximately five years.	Ongoing since 2020	Improves Board effectiveness and responsiveness to evolving business needs through a refreshed and diverse skill set.
Board Size	The Board adopted a resolution in January 2026 setting the number of directors at ten.	January 2026	Maintains an appropriate size for effective oversight and strategic guidance.
Board Classification	Nomination of Lynne N. Ward for a one-year term to balance the three classes of directors, following Fred P. Lampropoulos's resignation.	May 13, 2026 (if elected)	Ensures balanced director terms as contemplated by the company's bylaws, promoting orderly succession.
Director Retirement Policy	The Board declined to accept Thomas J. Gunderson's resignation despite him reaching the age of 75, citing his significant contributions and unique perspective.	Ongoing	Allows for the retention of valuable, experienced directors on a case-by-case basis, balancing policy with individual contribution and company needs.
Risk Management Oversight	The Board delegated risk management oversight to the Finance Committee, with specific risks (e.g., cybersecurity, human capital development, sustainability) further delegated to applicable standing committees.	2025	Provides structured and specialized oversight of various risk areas, enhancing the company's ability to identify, assess, and mitigate potential challenges.
Shareholder Engagement	Enhanced engagement efforts, including consultations with external advisors, leading to strengthened corporate governance and executive compensation practices.	2025	Increases alignment with shareholder interests and improves governance practices based on stakeholder feedback.
Stock Ownership Guidelines	Directors, the CEO, and other NEOs are required to maintain minimum stock ownership (5x annual retainer for directors, 5x base salary for CEO, 3x base salary for other NEOs). All current individuals are in compliance or within their five-year transition periods.	Ongoing	Aligns the long-term interests of leadership with those of shareholders and mitigates excessive risk-taking behaviors.
Clawback Policy	Adopted the Executive Incentive Compensation Clawback Policy (effective October 2, 2023) to recoup erroneously awarded incentive-based compensation due to material financial reporting restatements.	October 2, 2023	Enhances accountability and aligns executive compensation with accurate financial reporting, complying with SEC regulations.
Insider Trading Policy	Reviewed and amended the Corporate Policy on Insider Trading, prohibiting short-term trading, short sales, derivatives, hedging, gifts during blackout periods, and holding securities in margin accounts or pledging.	2025 (amended)	Promotes compliance with insider trading laws and protects the company's reputation and market integrity.
Equity Incentive Plan	Proposal to approve the Merit Medical Systems, Inc. 2026 Equity Incentive Plan, authorizing 2,700,000 shares, replacing the 2018 plan. The plan includes features such as annual limits on non-employee director compensation, limited transferability, forfeiture events, one-year minimum vesting, no dividends on unvested awards, no automatic share reserve increase, no repricing, no liberal recycling of shares, and double-trigger accelerated vesting on Change in Control.	May 13, 2026 (if approved)	Aligns employee and shareholder interests, attracts and retains talent, and incorporates best practices in equity compensation governance, reducing potential dilution risks.
Employee Stock Purchase Plan	Proposal to approve the Merit Medical Systems, Inc. 2026 Employee Stock Purchase Plan, authorizing 500,000 shares, replacing the 1996 plan. The plan is intended to qualify under Section 423 of the Code, allowing eligible employees to purchase shares at a 5% discount.	July 1, 2026 (if approved)	Provides a significant benefit to employees, fostering ownership and aligning their interests with shareholders, thereby aiding in talent attraction and retention.

Legal Proceedings

Historical costs incurred in responding to an inquiry from the U.S. Department of Justice (DOJ) and complying with the company's corporate integrity agreement with the DOJ.
Historical legal costs associated with a shareholder derivative proceeding in 2022.
Accrued class action litigation settlement costs of $10 million in 2021, net of insurance proceeds.
Accrued contract termination costs of approximately $6 million in 2021 to renegotiate certain terms of an acquisition agreement.

Related Party Transactions

Sales of products totaling approximately $4.2 million in revenue to hospitals within the SSM Health system for the year ended December 31, 2025. Laura S. Kaiser, a Board member, serves as President and CEO of SSM Health, but had no personal interest in or otherwise benefited from these purchases.
Sales of products totaling approximately $124,000 in revenue to TransMedics Group, Inc. for the year ended December 31, 2025. Thomas J. Gunderson, a Board member, serves as a director of TransMedics Group, Inc., but had no personal interest in or otherwise benefited from these purchases.

Stakeholder Impact

Shareholders: Benefit from strong financial performance, increased shareholder returns, enhanced corporate governance, and alignment of executive compensation with shareholder value through performance-based awards and stock ownership guidelines.
Employees: Experience a smooth leadership transition, receive one-time equity retention awards for key non-CEO NEOs, participate in a company-wide compensation and bonus program, benefit from improved employee engagement initiatives, and have the opportunity to participate in a proposed new Employee Stock Purchase Plan to foster ownership.
Customers: Benefit from continued innovation with new product launches (e.g., Ventrax Delivery System, MAK Gold Mini Access Kits), strategic acquisitions expanding the product portfolio (e.g., StatSeal, WoundSeal, C2 CryoBalloon), and the company's commitment to providing high-quality, safe, and effective products.
Suppliers: The company's Human Rights and Labor Standards Policy indicates a focus on assessing and mitigating risks of unlawful or harmful labor practices within the supply chain, promoting ethical sourcing.
Communities/Environment: The company demonstrates commitment to reducing its environmental footprint (waste, water, greenhouse gas emissions), maintaining ISO certifications for environmental management, and engaging in philanthropic contributions focused on youth development, health and well-being, veterans, and STEM education.

Next Steps

Hold the 2026 Annual Meeting of Shareholders virtually on May 13, 2026.
Release the 2025 Corporate Sustainability Report in May 2026.
Continue execution of the CGI Program towards its three-year targets ending December 31, 2026.
Receive potential contingent payments up to $3 million in 2026 for the C2 CryoBalloon acquisition upon meeting certain milestones.
Martha G. Aronson will participate in the company's annual bonus plans commencing in fiscal year 2026.
Fred P. Lampropoulos's consulting agreement with the company will conclude on March 31, 2026.
Continue construction of the 212,000 square foot distribution facility adjacent to the Utah headquarters.
Continue patient enrollment in the WRAPSODY (WRAP) North American Registry and the PREEMIE Study (BLOOM Micro-Occluder System).
The Governance Committee will continue its annual review of director independence and the new three-year Board evaluation process.
The 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan will become effective if approved by shareholders at the Annual Meeting.

Key Dates

Date	Description
2015-07-01	F. Ann Millner, Ed.D. became Director.
2017-10-01	Director Retirement Policy (age 75) amended.
2019-08-01	Lynne N. Ward became Director.
2020-06-01	Lonny J. Carpenter and David K. Floyd became Directors.
2020-12-11	Michel J. Voigt assumed Chief Human Resources Officer position.
2020-12-31	Start of the five-year cumulative total return (TSR) period.
2021-03-19	Brian G. Lloyd option grant.
2021-06-01	Stephen C. Evans became Director.
2021-08-19	Neil W. Peterson option grant.
2022-02-28	Raul Parra, Brian G. Lloyd, Michel J. Voigt, Fred P. Lampropoulos option grants.
2022-05-01	Laura S. Kaiser and Michael R. McDonnell became Directors.
2023-02-28	Raul Parra, Neil W. Peterson, Brian G. Lloyd, Michel J. Voigt, Fred P. Lampropoulos option grants.
2023-05-18	Annual meeting of shareholders where frequency of advisory votes on executive compensation was approved annually.
2023-06-08	Fred P. Lampropoulos's Amended and Restated Employment Agreement dated.
2023-10-02	Merit Medical Systems, Inc. Executive Incentive Compensation Clawback Policy adopted.
2023-12-31	Foundations for Growth Program concluded.
2024-03-04	Raul Parra, Neil W. Peterson, Brian G. Lloyd, Michel J. Voigt, Fred P. Lampropoulos RSU grants.
2024-05-01	Silvia M. Perez became Director.
2024-07-01	Acquisition of products from Endogastric Solutions, Inc.
2024-10-01	C. Adam Smith became Executive Vice President, U.S. and EMEA. Acquisition of products from Cook Medical Holdings LLC.
2025-02-25	2024 Annual Report on Form 10-K filed with the SEC.
2025-02-28	Raul Parra, Neil W. Peterson, Brian G. Lloyd, Michel J. Voigt, Fred P. Lampropoulos RSU and PSU grants.
2025-05-01	Merger transaction with Biolife Delaware, L.L.C. completed. Annual Meeting of Shareholders held, with approximately 97% support for executive compensation.
2025-05-25	C. Adam Smith's Form 3 due date.
2025-06-11	C. Adam Smith's Form 3 filed (late).
2025-10-03	Martha G. Aronson became President and CEO. Fred P. Lampropoulos resigned as President and CEO, transitioning to Executive Chair of the Board.
2025-11-03	Acquisition of the C2 CryoBalloon device and related technology from Pentax of America, Inc. completed.
2025-12-31	Fiscal year end. Second year of the CGI Program completed.
2026-01-03	Fred P. Lampropoulos's employment as Executive Chair terminated.
2026-01-04	Fred P. Lampropoulos resigned as a director and Chair of the Board.
2026-01-05	F. Ann Millner, Ed.D. appointed Chair of the Board.
2026-01-07	Consulting agreement with Fred P. Lampropoulos commenced.
2026-02-24	2025 Annual Report on Form 10-K filed with the SEC.
2026-02-26	One-time equity retention awards (RSUs) granted to certain non-CEO NEOs. PSUs granted in 2023 vested.
2026-03-05	PSU Cash Incentive paid to Mr. Lampropoulos for 2023 awards.
2026-03-20	Record Date for the 2026 Annual Meeting of Shareholders.
2026-03-31	Consulting agreement with Fred P. Lampropoulos ends.
2026-04-02	Proxy materials for the 2026 Annual Meeting first mailed or made available to shareholders.
2026-05-08	Deadline for voting instructions for shares held in the 401(k) Profit Sharing Plan.
2026-05-12	Deadline for phone and internet voting (for shares held directly) prior to the Annual Meeting.
2026-05-13	2026 Annual Meeting of Shareholders held virtually.
2026-05-15	Restricted stock units granted to non-employee directors in 2025 are scheduled to vest.
2026-05-01	Upcoming 2025 Corporate Sustainability Report scheduled for release.
2026-06-30	The 1996 Employee Stock Purchase Plan (ESPP) is scheduled to expire.
2026-07-01	Effective date of the 2026 Employee Stock Purchase Plan, if approved by shareholders.
2026-12-03	Deadline for shareholder proposals to be considered for inclusion in the 2027 annual meeting proxy materials.
2026-12-14	Earliest date for shareholders to submit proposals (not for inclusion in proxy) for the 2027 annual meeting.
2027-01-13	Latest date for shareholders to submit proposals (not for inclusion in proxy) for the 2027 annual meeting.
2027-03-14	Deadline for shareholder notice for proxy solicitation in support of nominees for the 2027 annual meeting.
2027-12-31	Proposed term expiration for Lynne N. Ward, Stephen C. Evans, and Silvia M. Perez if elected.
2028-12-31	Proposed term expiration for Thomas J. Gunderson, Laura S. Kaiser, Michael R. McDonnell, and F. Ann Millner, Ed.D. The 2018 Incentive Plan is scheduled to expire.
2029-12-31	Proposed term expiration for Martha G. Aronson, Lonny J. Carpenter, and Scott R. Ward if elected.
2036-06-30	The 2026 Employee Stock Purchase Plan is scheduled to expire.

Recommendation

buy

The company's record revenue, strong profitability growth, and successful execution of strategic initiatives, including key acquisitions and a smooth CEO transition, demonstrate robust operational health and a clear path for future growth. While the 5-year TSR lags the broader peer group, the recent performance and forward-looking plans suggest a positive trajectory. The enhanced corporate governance and employee incentive programs further strengthen the company's foundation, making it an attractive investment for long-term growth.

Keywords

Medical Devices, Healthcare, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Financial Performance, Acquisitions, Product Development, Sustainability, Shareholder Meeting, Merit Medical Systems, MMSI

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.